Correlation of C3 level with severity of generalized myasthenia gravis

Muscle and Nerve

Volumn 40, Issue 5, 2009, Pages 801-808

  Liu, Aidong ^a   Lin, Hong ^a   Liu, Yu ^a   Cao, Xinsheng ^b   Wang, Xianni ^a   Li, Zhuyi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acetylcholine receptor antibody; Complement 3; Myasthenia gravis; Quantitative myasthenia gravis scores

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; COMPLEMENT COMPONENT C3; PREDNISONE; PYRIDOSTIGMINE;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DISEASE SEVERITY; FEMALE; GENETIC DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; COMPLEMENT C3; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; YOUNG ADULT;

EID: 71549116710     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21398     Document Type: Article

References (36)

1. Lefvert AK, Bergström K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978;41:394-403. (Pubitemid 8323892)
2. Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, et al. Treatment of MG exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol 2005;62:1689-1693. (Pubitemid 41626664)
3. Husain AM, Massey JM, Howard JF, Sanders DB. Acetylcholine receptor antibody measurements in acquired myasthenia gravis. Diagnostic sensitivity and predictive value for thymoma. Ann NY Acad Sci 1998;841:471-474.
4. Jitpimolmard S, Taimkao S, Chotmongkol V, Sawanyawisuth K, Vincent A, Newsom-Davis J. Acetylcholine receptor antibody in Thai generalized myasthenia gravis patients. J Med Assoc Thai 2006;89:68-71. (Pubitemid 43275752)
5. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-1066.
6. Nakano S, Engel AG. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 1993;43:1167-1172. (Pubitemid 23177718)
7. Chamberlain-Banoub J, Neal JW, Mizuno M, Harris CL, Morgan BP. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 2006; 146:278-286. (Pubitemid 44581343)
8. Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Ann Ital Med Int 1996;11:119-124.
9. Loutrari H, Tzartos SJ, Claudio T. Use of Torpedo-mouse hybrid acetylcholine receptors reveals immunodominance of the α subunit in myasthenia gravis antisera. Eur J Immunol 1992;22:2949-2956.
10. Kuncl RW, Drachman DB, Adams R, Lehar M. 3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptors. J Pharmacol Exp Ther 1993;267:582-589. (Pubitemid 23352510)
11. Tüzün E, Saini SS, Ghosh S, Rowin J, Meriggioli MN, Christadoss P. Predictive value of serum anti-C1q antibody level in experimental autoimmune myasthenia gravis. Neuromuscul Disord 2006;16:137-143.
12. Kuttner-Kondo LA, Dybvig MP, Mitchell LM, Muqim N, Atkinson JP, Medof ME, et al. A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases. J Biol Chem 2003;278:52386-52391.
13. Besinger UA, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983;33:1316-1321.
14. Motomura M, Fukuda T, Yoshimura T, Tsujihata M. Overview: MuSK/Dok-7. Nippon Rinsho 2008;66:1140-1148.
15. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-1059.
16. Pták J, Lochman J. Immunoadsorption therapy and complement activation. Transfus Apher Sci 2005;32:263-267.
17. Zimmermann-Nielsen E, Grønbaek H, Dahlerup JF, Baatrup G, Thorlacius-Ussing O. Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis. BMC Gastroenterol 2005;5:31-37.
18. Najam FI, Giasuddin AS, Shembesh AH. Complement components (C3, C4) in childhood asthma. Indian J Pediatr 2005;72:745-749.
19. Zimmer B, Hartung HP, Scharfenberger G, Bitter-Suermann P, Hadding U. Quantitative studies of the secretion of complement C3 by resident, elicited and activated macrophages. Comparison with C2, C4 and lysosomal enzyme release. Eur J Immunol 1982;12:426-430.
20. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for complement proteins C3 and C4: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 2004;18:1-8. (Pubitemid 38176995)
21. Engström G, Hedblad B, Eriksson KF, Janzon L, Lindgärde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005;54: 570-575.
22. Tüzün E, Scott BG, Goluszko E, Higgs S, Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune MG. J Immunol 2003;171:3847-3854. (Pubitemid 37264927)
23. Paul E, Pozdnyakova OO, Mitchell E, Carroll MC. Anti-DNA autoreactivity in C4-deficient mice. Eur J Immunol 2002;32: 2672-2679.
24. Sahashi K, Engel AG, Lindstrom J, Lambert EH, Lennon VA. Ultrastructural localisation of immune complexes (IgG and C3) at the endplate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol 1978;37:212-223. (Pubitemid 8318389)
25. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006;116:2843-2854. (Pubitemid 44684466)
26. Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2003;2:99-106. (Pubitemid 37443330)
27. Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005;57:289-293.
28. Atkinson JP, Frank MM. Effect of cortisone therapy on serum complement components. J Immunol 1973;111: 1061-1066.
29. Jansen NJ, van Oeveren W, van Vliet M, Stoutenbeek CP, Eysman L, Wildevuur CR. The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass. Eur J Cardiothorac Surg 1991;5:211-217.
30. Rhodes JM, Bartholomew TC, Jewell DP. Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut 1981; 22:642-647.
31. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999;22: 1479-1497.
32. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-486. (Pubitemid 32097072)
33. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735. (Pubitemid 24348207)
34. Lutz HU, Stammler P, Jelezarova E, Nater M, Späth PJ. High doses of immunoglobulin G attenuate immune aggregate- mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88:184-193. (Pubitemid 26230686)
35. Lutz HU, Stammler P, Bianchi V, Trüeb RM, Hunziker T, Burger R, et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 2004;103:465-472.
36. Christadoss P, Tüzün E, Li J, Saini SS, Yang H. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Ann NY Acad Sci 2008;1132: 210-219. (Pubitemid 351841352)